Oncology On targeted radiotherapeutics, with Marc Hedrick Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.
News Pfizer takes 25-valent Prevnar follow-up into phase 3 Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
